JSR Expands its Biomedical Business by Investing in BIA Separations' Unique Purification Technology

JSR Corporation and BIA Separations have announced that they have entered a strategic partnership which includes a minor equity position by JSR on November 14th 2011. As a result of this investment, JSR and BIA Separations have started a joint global marketing and sales effort and collaborative R&D activities in the area of downstream purification as part of the manufacturing of vaccine, DNA and antibody based medicines.

From JSR’s perspective, teaming up with BIA Separations will give JSR access to a unique and leading edge technology in the field of downstream purification of large bio-molecules. Combining this technology with JSR’s proprietary Protein A media, the bio pharmaceutical industry will be offered afaster, more reliable downstream  purification process at a lower cost of ownership. This will contribute to making advanced treatments

accessible to a larger part of the human society.

JSR’s global presence in the local markets and JSR’s expertise in the field of consistent high quality volume manufacturing will help BIA  separations to successfully grow its business while maintaining its technological leadership.